en · de · es · fr · pt
cardarine-notes.peptides4800.com › Faq › Detection And Regulatory Landscape — Evidence Review

Detection And Regulatory Landscape — Evidence Review

By Editorial Desk · published 2026-02-09 · last reviewed 2026-03-22 · Faq

This is a working overview of fatty acid oxidation, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-03-22 and is reviewed periodically as new material appears.

Detection and Regulatory Landscape

A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.

Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.

Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.

Mechanism and Detection Methods

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.

Cardarine at a glance

PropertyValueNotes
Regulatory statusProhibited in sportListed by WADA as a PPARδ agonist.
Typical detection matrixUrineMost common sample for anti-doping analysis.
Common analytical methodLC-MS/MSLiquid chromatography-tandem mass spectrometry.
Common synonymsGW501516, GSK-516, endurobolNames found in research and fitness contexts.
Typical detection windowVariableDepends on dose, route, and individual metabolism.

Regulatory Status and Detection Context

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

Related pages on this site

Regulation and Analytical Detection

Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.

Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.

Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.

Cardarine Identity and Mechanism

Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.

At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.

Mechanism and Laboratory Detection

GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Further detail

Some instruments measure the average amount of hemoglobin in each reticulocyte; a parameter that has been studied as an indicator of iron deficiency in people who have conditions that interfere with standard tests. The immature reticulocyte fraction (IRF) is another measurement produced by some analyzers which quantifies the maturity of reticulocytes: cells that are less mature contain more RNA and thus produce a stronger fluorescent signal. This information can be useful in diagnosing anemias and evaluating red blood cell production following anemia treatment or bone marrow transplantation.

== External links == Royal Society of Chemistry, Historical Group, short biography of Curtius University of Kiel history of the inorganic department Heidelberg University German Alpen Association, Kiel section

=== Research limitations === Inconsistencies in dosing, purity, and concomitant drug use makes evaluating the effects of mitragynine in humans difficult. Conversely, animal studies control for such variability, but offer limited translatable information relevant to humans. Experimental limitations aside, mitragynine has been found to interact with a variety of receptors, although the nature and extent of receptor interactions has yet to be fully characterized. Additionally, the toxicity of mitragynine and associated kratom alkaloids has yet to be fully determined in humans, nor has the risk of overdose. More studies are necessary to assess safety and potential therapeutic utility.

=== Clinical trials === In a 2010, clinical trial, 34% of patients with refractory Hodgkin lymphoma achieved complete remission and another 40% had partial remission. Tumor reductions were achieved in 94% of patients. In ALCL, 87% of patients had tumors shrink at least 50% and 97% of patients had some tumor shrinkage. Reports in 2013, showed interim results from a Phase II, open-label, single-arm study designed to evaluate the antitumor activity of brentuximab vedotin in relapsed or refractory CD30-positive NHL, including B-cell neoplasms. These results demonstrated that single-agent brentuximab vedotin induced a 42% objective response rate and manageable safety profile among advanced diffuse large B-cell lymphoma patients. A phase III trial funded by Millennium Pharmaceuticals compared ABVD (a combination of the chemotherapy drugs doxorubicin, bleomycin, vinblastine, and dacarbazine) versus A+AVD (a combination of brentuximab vedotin plus AVD, or doxorubicin, vinblastine, and dacarbazine) for treatment of classical Hodgkin lymphoma and found substituting brentuximab vedotin for bleomycin has both improved efficacy and lowered toxicity. A previously completed phase I study demonstrated that a greater number of patients experienced pulmonary toxicity with brentuximab vedotin-ABVD than with ABVD alone. Pulmonary fibrosis is a classical adverse effect of bleomycin; however, the incidence of pulmonary fibrosis in the brentuximab vedotin-ABVD arm was higher than the expected historical rate with ABVD alone.

Sources: en.wikipedia.org

Background from the literature

== References == Butler, Rohan, MA., Bury, J.P.T., MA., & Lambert M.E., MA., editors, Documents on British Foreign Policy 1919–1939, 1st Series, Her Majesty's Stationery Office, London, 1960, vol. x, Chapter VIII, "The Plebiscites in Allenstein and Marienwerder January 21 – September 29, 1920" Keynes, John Maynard. A Revision of the Treaty: Being a Sequel to The Economic Consequences of the Peace, Harcourt, Brace, 1922 Kossert, Andreas. Masuren: Ostpreussens vergessener Süden, ISBN 3-570-55006-0 (in German) Mayer, S. L., MA. History of the First World War – Plebiscites:Self Determination in Action, Peter Young, MA., editor, BPC Publishing Ltd., UK., 1971. Rhode, Gotthold. Die Ostgebiete des Deutschen Reiches, Holzner-Verlag Würzburg, 1956. Tooley, T. Hunt. National Identity and Weimar Germany: Upper Silesia and the Eastern Border, 1918–1922, U of Nebraska Press, 1997, ISBN 0-8032-4429-0 Topolski, Jerzy. An Outline History of Poland, Interpress, 1986, ISBN 83-223-2118-X Wambaugh, Sarah. Plebiscites since the World War, Washington DC, 1933. I pp 99–141; II pp 48–107 Williamson, David G. The British in Germany 1918–1930, Oxford, 1991, ISBN 0-85496-584-X

Hong Kong has the world's largest number of skyscrapers, with 554 towers taller than 150 metres (490 ft), and the third-largest number of high-rise buildings in the world. The lack of available space restricted development to high-density residential tenements and commercial complexes packed closely together on buildable land. Single-family detached homes are uncommon and generally only found in outlying areas. The International Commerce Centre and Two International Finance Centre are the tallest buildings in Hong Kong and are among the tallest in the Asia-Pacific region. Other distinctive buildings lining the Hong Kong Island skyline include the HSBC Main Building, the anemometer-topped triangular Central Plaza, the circular Hopewell Centre, and the sharp-edged Bank of China Tower.

=== Attenuance === Absorbance is a number that measures the attenuation of the transmitted radiant power in a material. Attenuation can be caused by the physical process of "absorption", but also reflection, scattering, and other physical processes. Absorbance of a material is approximately equal to its attenuance when both the absorbance is much less than 1 and the emittance of that material (not to be confused with radiant exitance or emissivity) is much less than the absorbance. Indeed,

Sources: en.wikipedia.org

Further detail

== Research career == After obtaining his Ph.D., his first job was in research for Parke, Davis and Company, and his first task was to isolate the hormone associated with the thyroid gland. He continued this research at St. Luke's Hospital in New York until 1914. He was appointed Head of the Biochemistry Section in the Graduate School of the Mayo Foundation, and the following year he was appointed as the Director of the Division of Biochemistry. Kendall made several significant contributions to biochemistry and medicine. His most important discovery was the isolation of thyroxine, although it was not the work for which he received the most accolades. Along with associates, Kendall was involved with the isolation of glutathione and determining its structure. He also isolated several steroids from the adrenal gland cortex, one of which was initially called Compound E. Working with Mayo Clinic physician Philip Showalter Hench, Compound E was used to treat rheumatoid arthritis. The compound was eventually named cortisone. In 1950, Kendall and Hench, along with Swiss chemist Tadeus Reichstein were awarded the 1950 Nobel Prize in Physiology or Medicine for "their discoveries relating to the hormones of the adrenal cortex, their structure and biological effects." His Nobel lecture focused on the basic research that led to his award, and was titled "The Development of Cortisone As a Therapeutic Agent." As of the 2010 awards, Kendall and Hench were the only Nobel Laureates to be affiliated with Mayo Clinic.

Nasal insufflation (known colloquially as "snorting", "sniffing", or "blowing") is a common method of ingestion of recreational powdered cocaine. The drug coats and is absorbed through the mucous membranes lining the nasal passages. Cocaine's desired euphoric effects are delayed when snorted through the nose by about five minutes. This occurs because cocaine's absorption is slowed by its constricting effect on the blood vessels of the nose. Insufflation of cocaine also leads to the longest duration of its effects (60–90 minutes). When insufflating cocaine, absorption through the nasal membranes is approximately 30–60% Most banknotes have traces of cocaine on them; this has been confirmed by studies done in several countries. In 1994, the US 9th Circuit Court of Appeals cited findings that in Los Angeles, three out of four banknotes were tainted by cocaine or another illicit drug. Snuff spoons, hollowed-out pens, cut straws, pointed ends of keys, long fingernails or artificial nails, and tampon applicators are also used to insufflate cocaine. The cocaine typically is poured onto a flat, hard surface and divided into "bumps", "lines", or "rails", and then insufflated. A 2001 study reported that the sharing of straws used to "snort" cocaine can spread blood diseases such as hepatitis C.

Although both acids cause a Pd+ orange to orange-red medulla reaction, a potassium (K) spot test can separate the species: the medulla of P. perlatum turns yellow (K+ yellow), whereas in P. stuppeum, the yellow colour turns red (K+ yellow turning red). Parmotrema perlatum can be distinguished from other sorediate and marginally ciliate species like P. arnoldii and P. robustum by the presence of the stictic acid chemosyndrome. Also, the medulla of P. arnoldii fluoresces strongly when lit with an ultraviolet lamp. Parmotrema perlatum is similar to P. crinitum due to both species having a brown to tan, erhizinate marginal zone and the presence of the stictic acid chemosyndrome in the medulla. However, P. crinitum can be distinguished by its isidiate upper surface. Another potential lookalike, P. margaritatum, is distinguished from P. perlatum by the K+ (red) reaction of its medulla. Cetrelia cetrarioides has been documented as a lookalike, presumably because of the cilia on its thallus margin, and the presence of atranorin and the stictic acid chemosyndrome.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine banned in sports?

Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.

How is cardarine detected?

Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.

Is cardarine legal to buy?

Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.

What receptor does cardarine target?

Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.

Network